MET and non-small cell lung carcinoma: Indeed, A-to-I edited miR-411–5p directly suppressed MET and the ERK/MAPK pathway, leading to enhanced sensitivity to gefitinib and osimertinib in TKI-resistant NSCLC cell lines.